GLP5 (GLP3 R + Cagrilintide (Omeglatide))
$159.99
In stock
Description
GLP5 is a research formulation combining GLP-3 R with cagrilintide, a long-acting amylin analogue. The pairing brings together two mechanistically distinct peptide systems that researchers are studying in the context of metabolic regulation and energy homeostasis.
The GLP-3 R component targets a receptor subtype within the GLP family, expressed in intestinal enteroendocrine cells and implicated in nutrient-sensing and gut-derived signaling pathways. GLP-3 is processed from proglucagon alongside GLP-1 and GLP-2, though its receptor pharmacology and downstream effector pathways remain an active area of investigation. Engineered analogues designed for GLP-3R selectivity are used in research settings to isolate receptor-specific responses from the broader incretin axis.
Cagrilintide is a fatty-acid-acylated amylin analogue developed for extended half-life. It acts on amylin receptors, which are heteromeric complexes formed by the calcitonin receptor paired with receptor activity-modifying proteins (RAMPs). These receptors are distributed in the area postrema, hypothalamus, and brainstem, regions involved in satiety signaling and the coordination of postprandial metabolic responses. Relative to native amylin, cagrilintide demonstrates prolonged receptor engagement and resistance to enzymatic degradation.
The GLP-3R agonist and cagrilintide combination is of research interest due to the complementary receptor systems involved. GLP-3R signaling operates through intestinal and enteric mechanisms, while amylin receptor activation engages central neural circuits. Researchers studying multi-receptor approaches to metabolic modulation use formulations such as GLP5 to examine how these distinct pathways interact when activated together.
GLP3 R
5mg
Cagrilintide
0.5mg
GLP5 is a research formulation combining GLP-3 R with cagrilintide, a long-acting amylin analogue. The pairing brings together two mechanistically distinct peptide systems that researchers are studying in the context of metabolic regulation and energy homeostasis.
The GLP-3 R component targets a receptor subtype within the GLP family, expressed in intestinal enteroendocrine cells and implicated in nutrient-sensing and gut-derived signaling pathways. GLP-3 is processed from proglucagon alongside GLP-1 and GLP-2, though its receptor pharmacology and downstream effector pathways remain an active area of investigation. Engineered analogues designed for GLP-3R selectivity are used in research settings to isolate receptor-specific responses from the broader incretin axis.
Cagrilintide is a fatty-acid-acylated amylin analogue developed for extended half-life. It acts on amylin receptors, which are heteromeric complexes formed by the calcitonin receptor paired with receptor activity-modifying proteins (RAMPs). These receptors are distributed in the area postrema, hypothalamus, and brainstem, regions involved in satiety signaling and the coordination of postprandial metabolic responses. Relative to native amylin, cagrilintide demonstrates prolonged receptor engagement and resistance to enzymatic degradation.
The GLP-3R agonist and cagrilintide combination is of research interest due to the complementary receptor systems involved. GLP-3R signaling operates through intestinal and enteric mechanisms, while amylin receptor activation engages central neural circuits. Researchers studying multi-receptor approaches to metabolic modulation use formulations such as GLP5 to examine how these distinct pathways interact when activated together.
